FDA Inspection 1251663 — Rashmi Singh, M.D.
The FDA completed an inspection of Rashmi Singh, M.D. on Aug 2, 2024 in Varanasi. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 2, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Varanasi (India)
Additional Details
Clinical BA/BE